Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Anne Louise Tølbøll Sørensen
Modality
monoclonal_antibody
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
70High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07474961CT.gov BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases. | — | Not Yet Recruiting | — | — | — |
NCT07637578CT.gov A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma | — | Not Yet Recruiting | — | — | — |
NCT07247097CT.gov ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma | — | Not Yet Recruiting | — | — | — |
NCT07382739CT.gov A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD" | — | Recruiting | — | — | — |
NCT07280013CT.gov A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects | — | Recruiting | — | — | — |
NCT06988488CT.gov A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT06997081CT.gov ERd Combination Treatment in Newly Diagnosed Multiple Myeloma | — | Recruiting | — | — | — |
NCT06832865CT.gov ELISA in Relapsed/Refractory MM | — | Recruiting | — | — | — |
NCT06974786CT.gov Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma | — | Recruiting | — | — | — |
NCT06918002CT.gov Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients | — | Recruiting | — | — | — |
Show 36 more trialsShow fewer
NCT06581848CT.gov Korean Post Marketing Surveillance for ELREXFIO (Elranatamab). | — | Active Not Recruiting | — | — | — |
NCT06947083CT.gov Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma | — | Recruiting | — | — | — |
NCT06931704CT.gov Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA) | — | Not Yet Recruiting | — | — | — |
NCT06421675CT.gov Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT06799026CT.gov A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT06015542CT.gov Self-administration of Subcutaneous Elranatamab in the Patients' Homes. | — | Recruiting | — | — | — |
NCT06855121CT.gov The Norwegian Immunotherapy in Multiple Myeloma Study | — | Recruiting | — | — | — |
NCT06483100CT.gov Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance | — | Recruiting | — | — | — |
NCT06711705CT.gov Elranatamab in Relapsed/Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT06645678CT.gov Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT06592222CT.gov A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies | — | Completed | — | — | — |
NCT06207799CT.gov Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma | — | Recruiting | — | — | — |
NCT06138275CT.gov Elranatamab in R/R Multiple Myeloma | — | Recruiting | — | — | — |
NCT06121843CT.gov A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT06215118CT.gov A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) | — | Recruiting | — | — | — |
NCT06152575CT.gov MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | — | Recruiting | — | — | — |
NCT06106945CT.gov AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma | — | Recruiting | — | — | — |
NCT06282978CT.gov Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes | — | Active Not Recruiting | — | — | — |
NCT06057402CT.gov Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) | — | Recruiting | — | — | — |
NCT06504524CT.gov A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US | — | Completed | — | — | — |
NCT05927571CT.gov A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) | — | Recruiting | — | — | — |
NCT05932290CT.gov A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT05675449CT.gov A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT05623020CT.gov A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant | — | Recruiting | — | — | — |
NCT05565391CT.gov A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT05317416CT.gov Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant | — | Active Not Recruiting | — | — | — |
NCT05228470CT.gov A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | — | Completed | — | — | — |
NCT05090566CT.gov MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma | — | Terminated | — | — | — |
NCT05014412CT.gov A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment | — | Completed | — | — | — |
NCT05020236CT.gov A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments | — | Recruiting | — | — | — |
NCT04798586CT.gov MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma | — | Completed | — | — | — |
NCT04649359CT.gov MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb | — | Active Not Recruiting | — | — | — |
NCT04068597CT.gov Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | — | Recruiting | — | — | — |
NCT03269136CT.gov PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT05238311CT.gov Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135) | — | No Longer Available | — | — | — |
NCT05462639CT.gov Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Plasma Cell Myeloma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Elranatamab (this asset) | Anne Louise Tølbøll Sørensen | Approved | BB · 66 |
| Hyaluronidase Fihj | Massachusetts General Hospital | P4 | BBB |
| Filanesib | PETHEMA Foundation | P2 | BBB |
| Vincristine Sulfate | Roswell Park Cancer Institute | P3 | BBB |
| Cyclosporin A | Seoul National University Hospital | P3 | BBB |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | University of Birmingham | P4 | BBB |
| Epoetin Alfa | Mayo Clinic | P3 | BB |
| Arsenic Trioxide | Duke University | P2 | BB |
| Sorafenib | OHSU Knight Cancer Institute | P2 | BB |
+42 more in the Plasma Cell Myeloma cohort
Other indications for Elranatamab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Waldenstrom Macroglobulinemia | — | P4 | BB · 65 |
| HIV Infectious Disease | — | P2/3 | B · 57 |
| Plasmablastic Lymphoma | — | P2/3 | CCC · 55 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Elranatamab in Plasma Cell Myeloma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/elranatamab-plasma-cell-myeloma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →